Statins for people at low risk of cardiovascular disease – Authors' reply

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833 · see citing works

Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations: A Statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology

Grundy, S. M., Pasternak, R., Greenland, P., Smith, S., & Fuster, V. (1999) · Circulation · doi:10.1161/01.cir.100.13.1481 · Cited by 1,315 · see citing works

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people

Collaborative, H. P. S. (2006) · BMJ · doi:10.1136/bmj.38993.731725.be · Cited by 109 · see citing works

Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens

Prepared by the Cholesterol Treatment Trialists' (CTT) Collaboration (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80744-9 · Cited by 101 · see citing works

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels

Heart Protection Study Collaborative Group (2009) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.808469 · Cited by 72 · see citing works

Statins for the primary prevention of cardiovascular disease

Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934 · see citing works

Statin Use and Reduced Cancer-Related Mortality

Klop, C., Driessen, J. H. M., & de Vries, F. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1214827 · Cited by 722 · see citing works

Epidemiological studies of CHD and the evolution of preventive cardiology

Wong, N. D. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.26 · Cited by 664 · see citing works

The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity

Borén, J., & Williams, K. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000330 · Cited by 524 · see citing works

Effects of aerobic exercise on lipids and lipoproteins

Wang, Y., & Xu, D. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0515-5 · Cited by 436 · see citing works

Statins in the primary prevention of cardiovascular disease

Reiner, Ž. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.80 · Cited by 312 · see citing works

Atherosclerosis

Schaftenaar, F. H., Frodermann, V., Kuiper, J., & Lutgens, E. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000302 · Cited by 268 · see citing works

Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

Zhang, X.-L., Zhu, Q.-Q., Zhu, L., Chen, J.-Z., Chen, Q.-H., Li, G.-N., Xie, J., Kang, L.-N., & Xu, B. (2015) · BMC Medicine · doi:10.1186/s12916-015-0358-8 · Cited by 260 · see citing works

Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease

Klarin, D. M., Program, V. A. M. V., Busenkell, E., Judy, R., Lynch, J. A., Levin, M. G., Haessler, J., Aragam, K. G., Chaffin, M. D., Haas, M., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0519-3 · Cited by 236 · see citing works

Impact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trial

Lockyer, S., Rowland, I. R., Spencer, J. P. E., Yaqoob, P., & Stonehouse, W. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1188-y · Cited by 237 · see citing works

Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017

Wein, T. H., Lindsay, M. P., Côté, R., Foley, N. C., Berlingieri, J., Bhogal, S. K., Bourgoin, A., Buck, B. H., Cox, J. L., Davidson, D., et al. (2017) · International Journal of Stroke · doi:10.1177/1747493017743062 · Cited by 223 · see citing works

Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis

Semb, A. G., Ikdahl, E., Wibetoe, G., Crowson, C. S., & Rollefstad, S. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0428-y · Cited by 216 · see citing works

Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System

McFarland, A. J., Anoopkumar‐Dukie, S., Arora, D. S., Grant, G. D., McDermott, C., Perkins, A. V., & Davey, A. K. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151120607 · Cited by 199 · see citing works

Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis

Macedo, A. F., Taylor, F. C., Casas, J. P., Adler, A. J., Prieto‐Merino, D., & Ebrahim, S. B. J. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-51 · Cited by 183 · see citing works

Improving prevention strategies for cardiometabolic disease

Sattar, N. A., Gill, J. M. R., & Alazawi, W. (2020) · Nature Medicine · doi:10.1038/s41591-020-0786-7 · Cited by 163 · see citing works

Clinical utility of polygenic risk scores for coronary artery disease

Klarin, D., & Natarajan, P. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00638-w · Cited by 152 · see citing works

Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk

His, M., Zelek, L. H., Deschasaux, M., Pouchieu, C., Kesse‐Guyot, E., Herçberg, S., Galan, P., Latino‐Martel, P., Blacher, J., & Touvier, M. (2014) · European Journal of Epidemiology · doi:10.1007/s10654-014-9884-5 · Cited by 145 · see citing works

Statins as Regulators of Redox State in the Vascular Endothelium: Beyond Lipid Lowering

Margaritis, M., Channon, K. M., & Antoniades, C. A. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5430 · Cited by 144 · see citing works

Cardiovascular risk assessment: a global perspective

Zhao, D. H., Liu, J., Xie, W., & Qi, Y. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.28 · Cited by 141 · see citing works

2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)

Committee for the Korean Guidelines for the Management of Dyslipidemia (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.3.275 · Cited by 124 · see citing works

Cheese consumption and risk of cardiovascular disease: a meta-analysis of prospective studies

Chen, G., Wang, Y., Tong, X., Szeto, I. M. Y., Smit, G., Li, Z., & Qin, L. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1292-z · Cited by 121 · see citing works

Demystifying the management of hypertriglyceridaemia

Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115 · see citing works

Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins

Pinho-Gomes, A. C., Reilly, S., Brandes, R. P., & Casadei, B. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5542 · Cited by 94 · see citing works

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk

Gatell, J. M., Assoumou, L., Moyle, G. J., Waters, L. J., Johnson, M. A., Domingo, P., Fox, J., Martínez, E., Stellbrink, H., Guaraldi, G., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001675 · Cited by 94 · see citing works

Evidence-based goals in LDL-C reduction

Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92 · see citing works

Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review

Canestaro, W. J., Austin, M. A., & Thummel, K. E. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.41 · Cited by 81 · see citing works

Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome

Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 81 · see citing works

Modelling survival: exposure pattern, species sensitivity and uncertainty

Ashauer, R., Albert, C., Augustine, S., Nina Cedergreen, G., Charles, S., Ducrot, V., Focks, A., Gabsi, F., Gergs, A., Goussen, B., et al. (2016) · Scientific Reports · doi:10.1038/srep29178 · Cited by 76 · see citing works

Statins and the autonomic nervous system

Millar, P. J., & Floras, J. S. (2013) · Clinical Science · doi:10.1042/cs20130332 · Cited by 75 · see citing works

Statins for primary prevention of cardiovascular disease

Minder, C. M., Blumenthal, R. S., & Blaha, M. J. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32836429e6 · Cited by 67 · see citing works

Synergistic effect of phytochemicals on cholesterol metabolism and lipid accumulation in HepG2 cells

Leng, E., Yuan, X., Mo, Z., Li, Y., Zhang, Y., Deng, X., Zhou, M., Zhou, C., He, Z., He, J., et al. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2189-6 · Cited by 66 · see citing works

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, H. M., Robinson, J. G., Farnier, M., Cariou, B., Blom, D. J., Kereiakes, D. J., Lorenzato, C., Pordy, R. C., & Chaudhari, U. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-121 · Cited by 61 · see citing works

Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial

Verhoeven, V., Hartmann, M. L., Remmen, R., Wens, J., Apers, S., & Royen, P. V. (2013) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-13-178 · Cited by 60 · see citing works

Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review

Bruckert, É., Parhofer, K. G., González‐Juanatey, J. R., Nordestgaard, B. G., Arca, M., Giovas, P. P., & Ray, K. K. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01285-2 · Cited by 59 · see citing works

Adding a life-course perspective to cardiovascular-risk communication

Karmali, K. N., & Lloyd‐Jones, D. M. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.185 · Cited by 57 · see citing works

Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM)

Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 58 · see citing works

Seventeen Years of Statin Pharmacogenetics: a Systematic Review

Leusink, M., Onland‐Moret, N. C., de Bakker, P. I. W., de Boer, A., & der Zee, A. H. M. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.158 · Cited by 56 · see citing works

Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?

de Lorgeril, M., Salen, P., Defaye, P., & Rabaeus, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-5 · Cited by 53 · see citing works

Comparison of cardiovascular disease risk calculators

Allan, G. M., Garrison, S., & McCormack, J. P. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000095 · Cited by 48 · see citing works

Tendinopathy and Tendon Rupture Associated with Statins

Deren, M. E., Klinge, S. A., Mukand, N. H., & Mukand, J. A. (2016) · JBJS Reviews · doi:10.2106/jbjs.rvw.15.00072 · Cited by 46 · see citing works

Hyperlipidemia is associated with lower risk of poststroke mortality independent of statin use: A population-based study

Yeramaneni, S., Kleindorfer, D., Sucharew, H. J., Alwell, K., Moomaw, C. J., Flaherty, M. L., Woo, D., Adeoye, O. M., Ferioli, S., Rosa, F. D. L. R. L., et al. (2016) · International Journal of Stroke · doi:10.1177/1747493016670175 · Cited by 47 · see citing works

Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy

Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45 · see citing works

Genetic susceptibility, elevated blood pressure, and risk of atrial fibrillation: a Mendelian randomization study

Nazarzadeh, M., Pinho‐Gomes, A., Bidel, Z., Canoy, D., Dehghan, A., Smith-Byrne, K., Bennett, D., Smith, G. D., & Rahimi, K. (2021) · Genome Medicine · doi:10.1186/s13073-021-00849-3 · Cited by 45 · see citing works

Recent advances in cardiovascular disease research driven by metabolomics technologies in the context of systems biology

Zhang, B., & Schmidlin, T. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00028-z · Cited by 48 · see citing works

Pharmacotherapies for lipid modification: beyond the statins

Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 44 · see citing works

Statin use and risk of bladder cancer: a meta-analysis

Zhang, X., Geng, J., Zhang, X., Peng, B., Che, J., Yang, Y., Wang, G., Xia, S., Yan, W. S., & Zheng, J. (2013) · Cancer Causes & Control · doi:10.1007/s10552-013-0159-3 · Cited by 42 · see citing works

Red clover isoflavones enriched with formononetin lower serum LDL cholesterol—a randomized, double-blind, placebo-controlled study

Clifton-Bligh, P. B., Nery, M. L., Clifton-Bligh, R. J., Visvalingam, S., Fulcher, G. R., Byth, K., & Baber, R. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.207 · Cited by 42 · see citing works

Increased triglyceride/high-density lipoprotein cholesterol ratio may be associated with reduction in the low-density lipoprotein particle size: assessment of atherosclerotic cardiovascular disease risk

Yokoyama, K., Tani, S., Matsuo, R., & Matsumoto, N. (2018) · Heart and Vessels · doi:10.1007/s00380-018-1247-9 · Cited by 41 · see citing works

Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies

Mitchell, S., Roso, S., Samuel, M., & Pladevall-Vila, M. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0241-3 · Cited by 40 · see citing works

Efficient design of clinical trials and epidemiological research: is it possible?

Lauer, M. S., Gordon, D., Wei, G. S., & Pearson, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.60 · Cited by 36 · see citing works

Serum lipids and risk of obesity-related cancers in postmenopausal women

Kabat, G. C., Kim, M., Chlebowski, R. T., Vitolins, M. Z., Wassertheil-Smoller, S. W., & Rohan, T. E. (2017) · Cancer Causes & Control · doi:10.1007/s10552-017-0991-y · Cited by 37 · see citing works

Cholesteryl ester transfer protein inhibitors: challenges and perspectives

Filippatos, T. D., Klouras, E., Barkas, F., & Elisaf, M. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1189327 · Cited by 33 · see citing works

Role of Small GTPase Protein Rac1 in Cardiovascular Diseases

Ferri, N., Contini, A., Bernini, S. K., & Corsini, A. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3182a18bcc · Cited by 32 · see citing works

Approach to Statin Use in 2016: an Update

Miller, P. E., & Martin, S. S. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0578-1 · Cited by 32 · see citing works

Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy?

Navarese, E. P., Szczesniak, A. M., Kołodziejczak, M. M., Górny, B., Kubica, J., & Suryapranata, H. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0053-0 · Cited by 32 · see citing works

Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone deacetylase inhibitor

Singh, R. S., Chaudhary, D. K., Mohan, A., Kumar, P., Chaturvedi, C. P., ECELBARGER, C. A., Godbole, M. M., & Tiwari, S. (2016) · Scientific Reports · doi:10.1038/srep38034 · Cited by 32 · see citing works

Treatment Gap in the National Health-screening Program in Korea: Claim-based Follow-up of Statin Use for Sustained Hypercholesterolemia

Ahn, E., Shin, D. W., Yang, H. K., Yun, J. M., Chun, S., Suh, B., Lee, H., Son, K. Y., & Cho, B. (2015) · Journal of Korean Medical Science · doi:10.3346/jkms.2015.30.9.1266 · Cited by 31 · see citing works

Statins to improve cardiovascular outcomes in treated HIV infection

Longenecker, C. T., Eckard, A. R., & McComsey, G. A. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000223 · Cited by 31 · see citing works

Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9

Chackerian, B., & Remaley, A. T. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000312 · Cited by 29 · see citing works

Association of classical risk factors and coronary artery disease in type 2 diabetic patients submitted to coronary angiography

Bittencourt, C., Piveta, V. M., Oliveira, C. S. V., Crispim, F., Meira, D. M., Saddi-Rosa, P., Giuffrida, F. M. A., & Reis, A. F. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-46 · Cited by 29 · see citing works

Communicating statin evidence to support shared decision-making

Barrett, B. P., Ricco, J. A., Wallace, M., KIEFER, D. M., & Rakel, D. (2016) · BMC Family Practice · doi:10.1186/s12875-016-0436-9 · Cited by 27 · see citing works

Hypothetical interventions to prevent stroke: an application of the parametric g-formula to a healthy middle-aged population

Vangen-Lønne, A. M., Ueda, P., Gulayin, P., Wilsgaard, T., Mathiesen, E. B., & Danaei, G. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-017-0344-x · Cited by 26 · see citing works

Early postpartum dyslipidemia and its potential predictors during pregnancy in women with a history of gestational diabetes mellitus

Pei, L., Xiao, H., Lai, F., Li, Z., Li, Z., Yue, S., Chen, H., Li, Y., & Cao, X. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01398-1 · Cited by 26 · see citing works

Can atherosclerosis be cured?

Wilkins, J. T., Gidding, S. S., & Robinson, J. G. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000644 · Cited by 26 · see citing works

The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups

Catapano, A. L., Toth, P. P., Tomassini, J. E., & Tershakovec, A. M. (2013) · Clinical Lipidology · doi:10.2217/clp.12.88 · Cited by 25 · see citing works

Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly

Lin, L., Teng, M., Zhao, Y. J., Khoo, A. L., Seet, R. C. S., Yong, Q. W., Yeo, T. C., & Lim, B. P. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6584-7 · Cited by 24 · see citing works

Pharmacogenomics of Lipid-Lowering Therapies

Hu, M., & Tomlinson, B. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.71 · Cited by 24 · see citing works

Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland

Ingimarsson, O., MacCabe, J. H., Haraldsson, M. H., Jónsdóttir, H., & Sigurðsson, E. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1334821 · Cited by 24 · see citing works

New insights into the role of glycosylation in lipoprotein metabolism

van den Boogert, M. A. W., Rader, D. J., & Holleboom, A. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000461 · Cited by 24 · see citing works

The optimal time of day for statin administration: a review of current evidence

Awad, K., & Banach, M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000524 · Cited by 23 · see citing works

Safety considerations with fenofibrate/simvastatin combination

Filippatos, T. D., & Elisaf, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1056778 · Cited by 22 · see citing works

Treatment of Dyslipidemia and Cardiovascular Outcomes: The Journey So Far—Is This the End for Statins?

Zoungas, S., Curtis, A. J., McNeil, J. J., & Tonkin, A. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.86 · Cited by 22 · see citing works

Exercise-induced Myalgia may Limit the Cardiovascular Benefits of Statins

Opie, L. H. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6483-8 · Cited by 21 · see citing works

Bio-inspired dual-functional phospholipid–poly(acrylic acid) brushes grafted porous poly(vinyl alcohol) beads for selective adsorption of low-density lipoprotein

Yu, Y., Dong, J., Ma, B., Jiang, X., Guo, C., Liu, Z., Chai, Y., Wang, L., Sun, L., Ou, L., et al. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb01220g · Cited by 21 · see citing works

Mouse Models of Disturbed HDL Metabolism

Hoekstra, M., & Eck, M. V. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_9 · Cited by 21 · see citing works

Comparing the serum TAG response to high-dose supplementation of either DHA or EPA among individuals with increased cardiovascular risk: the ComparED study

Allaire, J., Vors, C., Harris, W. S., Jackson, K. H., Tchernof, A., Couture, P., & Lamarche, B. (2019) · British Journal Of Nutrition · doi:10.1017/s0007114519000552 · Cited by 20 · see citing works

Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins

Andrade, C. (2013) · Bipolar Disorders · doi:10.1111/bdi.12130 · Cited by 18 · see citing works

Statins in the elderly

Zoungas, S., Curtis, A. J., Tonkin, A. M., & McNeil, J. J. (2014) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000082 · Cited by 18 · see citing works

A dysglycaemic effect of statins in diabetes: relevance to clinical practice?

Swerdlow, D. I., & Sattar, N. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3409-3 · Cited by 17 · see citing works

PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials

Rhainds, D., Arsenault, B. J., & Tardif, J. (2012) · Clinical Lipidology · doi:10.2217/clp.12.74 · Cited by 18 · see citing works

Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine

Bertrand, M. E., Vlachopoulos, C. V., & Mourad, J. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0175-2 · Cited by 17 · see citing works

Should apolipoprotein B replace LDL cholesterol as therapeutic targets are lowered?

Meeusen, J. W., Donato, L. J., & Jaffe, A. S. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000313 · Cited by 17 · see citing works

Treatment of homozygous familial hypercholesterolemia

France, M. W., Schofield, J. D., Kwok, S., & Soran, H. (2014) · Clinical Lipidology · doi:10.2217/clp.13.79 · Cited by 15 · see citing works

Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience

Farnier, M. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000356 · Cited by 13 · see citing works

Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer

Şendur, M. A. N., Aksoy, S., Yazıcı, O., Özdemir, N., Zengin, N., & Altundağ, K. (2013) · Medical Oncology · doi:10.1007/s12032-013-0835-x · Cited by 12 · see citing works

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline

Journath, G., Hambræus, K., Hagström, E., Pettersson, B., & Löthgren, M. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0659-2 · Cited by 12 · see citing works

Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin

Srisawasdi, P., Rodcharoen, P., Vanavanan, S., Chittamma, A., Sukasem, C., Nakorn, C. N., Dejthevaporn, C., & Kroll, M. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s278671 · Cited by 12 · see citing works

Prevention and control of cardiovascular disease in “real-world” settings: sustainable implementation of effective policies

Mendis, S., & Graham, I. M. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1380809 · Cited by 11 · see citing works

Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy

Ouwens, M., Nauta, J. J. P., Ansquer, J.-C., & Driessen, S. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1098597 · Cited by 11 · see citing works

Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial

Lonn, E. M., Jung, H., & Yusuf, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1608916 · Cited by 11 · see citing works

Clinical Characteristics of Patients With Statin Discontinuation in Korea: A Nationwide Population-Based Study

Kim, K., Hong, S., Han, K., & Park, C. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.41 · Cited by 10 · see citing works

Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202

Verma, A., Bradford, Y., Verma, S. S., Pendergrass, S. A., Daar, E. S., Venuto, C. S., Morse, G. D., Ritchie, M. D., & Haas, D. W. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000263 · Cited by 9 · see citing works

Diet and cardiovascular health in asymptomatic normo- and mildly-to-moderately hypercholesterolemic participants – baseline data from the BLOOD FLOW intervention study

Hallikainen, M., Halonen, J., Konttinen, J., Lindholm, H. J., Simonen, P. P., Nissinen, M. J., & Gylling, H. K. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-62 · Cited by 9 · see citing works

Drug Development Strategy for Type 2 Diabetes: Targeting Positive Energy Balances

Liu, Z., & Yang, B. (2018) · Current Drug Targets · doi:10.2174/1389450120666181217111500 · Cited by 8 · see citing works

Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease

Weng, S. F., Akyea, R. K., Man, K. K. C., Lau, W. C. Y., Iyen, B., Blais, J. E., Chan, E. W., Siu, C. W., Qureshi, N., Wong, I. C. K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260839 · Cited by 8 · see citing works

Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS)

Silva, P. M., Cardoso, S. M., & Ferreira, A. M. (2014) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2014.913605 · Cited by 8 · see citing works

Study of Consumer Acceptance About the Possible Commercialization of a Cheese with Berries

Ferrão, A. C., Guiné, R. P. F., & Correia, P. (2017) · Current Nutrition & Food Science · doi:10.2174/1573401313666170707103933 · Cited by 7 · see citing works

Drug treatment of dyslipidemia

Kim, S. (2016) · Journal of Korean Medical Association · doi:10.5124/jkma.2016.59.5.366 · Cited by 7 · see citing works

Comparison of statin eligibility according to the Adult Treatment Panel III, ACC/AHA blood cholesterol guideline, and presence of carotid plaque by ultrasound in Mexican mestizo patients with rheumatoid arthritis

Galarza-Delgado, D. Á., Azpiri-Lopez, J. R., Colunga-Pedraza, I. J., la Garza, J. A. C., Vera‐Pineda, R., Garcia-Colunga, J. I., Arvizu‐Rivera, R. I., Martinez‐Moreno, A., Villarreal‐Pérez, J. Z., Elizondo‐Riojas, G., et al. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3312-z · Cited by 7 · see citing works

Prevention of macrovascular disease in patients with short-duration type 2 diabetes by multifactorial target control: an 8-year prospective study

Wu, W., Ren, M., Cheng, H., Yan, L., Qi, Y., Yang, C. H., & Yan, L. (2014) · Endocrine · doi:10.1007/s12020-013-0158-x · Cited by 6 · see citing works

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833 · see citing works

Statins for people at low risk of cardiovascular disease

Mascitelli, L., & Goldstein, M. R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)62025-x · Cited by 5 · see citing works

Meta-analysis: Lowering LDL-C levels using statins reduces major vascular events regardless of baseline risk

Jain, M., & Rosenberg, M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-8-201210160-02002 · Cited by 4 · see citing works

Remediating “Lessons from the controversy over statins”

Abramson, J. D., Rosenberg, H. G., Jewell, N., & Wright, J. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30720-1 · Cited by 3 · see citing works

The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis

Delahoy, P. J., Magliano, D. J., Webb, K., Grobler, M. P., & Liew, D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.017 · Cited by 167 · see citing works